2,692 search results for “cancer drug discovery initiative” in the Public website
-
The diverse roles of integrin α3β1 in cancer: Lessons learned from skin and breast carcinogenesis
In this thesis, we aim to shed light on the diverse and often opposing roles of integrin α3β1 in cancer.
-
Using Liposomes; Opportunities for Treatment of Atherosclerosis and Cancer
This thesis focuses on using liposomes in two different treatment strategies; vaccination (or immunotherapy) and delivery of a small molecule, and in two different disease models; cancer and atherosclerosis.
-
Cryptic species discovery
Do understudied animals contain hidden species?
-
Antibiotic Discovery: From mechanistic studies to target ID
The investigations described in this thesis lay out strategies aimed at advancing antibiotic research and development. The examples presented revolve around two main approaches: understanding drug-target interactions and target identification.
-
Postdoc Computational Modeling for Drug Safety Prediction
Science, Leiden Academic Centre for Drug Research (LACDR)
-
Rethinking drug discovery: Vidi grant for Laura Heitman
Laura Heitman has been awarded a VIDI grant for her innovative drug research. Heitman strives to optimize a drug’s binding kinetics at its target in order to ultimately fight diseases effectively. She even pleads for a paradigm shift in drug discovery.
-
Prediction of spatial-temporal brain drug distribution with a novel mathematical model
A novel mathematical model describes spatial-temporal drug distribution within one or more brain units, which are cubic representations of a piece of brain tissue with brain capillaries at the edges.
-
Microneedle-based drug and vaccine delivery via nanoporous microneedle arrays
In the literature, several types of microneedles have been extensively described. However, porous microneedle arrays only received minimal attention. Hence, only little is known about drug delivery via these microneedles. However, porous microneedle arrays may have potential for future microneedle-based…
-
Time is of the essence: investigating kinetic interactions between drug, endogenous neuropeptides and receptor
Promotor: A.P. IJzerman Co-promotor: L.H. Heitman
-
Cell-autonomous and host-dependent CXCR4 signaling in cancer metastasis: insights from a zebrafish xenograft model
Promotor: A.H. Meijer, Co-promotor: B.E. Snaar-Jagalska
-
A community effort to assess and improve drug sensitivity prediction algorithms
Source: Nature Biotechnology, Volume 2014, Issue June (2014)
-
Cancer research focusing on quality of life
Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…
-
Gerard van Westen: 'Our model predicts what candidate drugs do in your body'
He’s a fast and animated speaker, which is only logical because Gerard van Westen is driving an express train. His destination? A virtual human, consisting of algorithms that predict what an administered substance will do in the body. The train is already a long way down the line and the pharmaceutical…
-
Sebastian Pomplun joins Oncode Institute to accelerate breakthroughs in cancer research
Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…
-
Advanced in vitro models for studying drug induced toxicity
Promotor: Prof.dr. B. van de Water, Co-promotor: L.S. Price
-
Drug-target binding kinetics in vivo
A next, general pharmacological problem to be tackled is how drug-target binding kinetics in vivo, affects target occupancy as an important indicator of the time-course of drug effects.
-
Drug-target residence time: a case for the adenosine A1 and A2A receptors
Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: Dr. L.H. Heitman
-
Drug use and harm reduction policies
Harm reduction in practice: a comparative analysis of the Dutch and Brazilian approach towards drug users.
-
New imaging technology to assess early drug success
Human and animal cells are very complex: very different chemical processes are going on at the same time, but they are separated from each other because the cells are divided in compartments. These compartments may also have a profound effect on the potential efficacy of therapeutics, because the drug…
-
Early Detection of Pancreatic Cancer in High-Risk Individuals
PhD defence
-
The chemistry behind cancer drugs: searching for fewer side effects
PhD candidate Dennis Wander searches for the best of both worlds. That is to say: a cancer drug that is effective and also has minimal side effects. To this end, he makes new molecules inspired by two existing medicines. And not without result: ‘We have created a new variant that is very promising.’…
-
namic Relationships of Central Nervous Systems Active Dopaminergic Drugs
Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.
-
Monitoring Cytoskeletal Conductance Variation for Sensing Cancer Drug Resistance
Actin and microtubules form cellular cytoskeletal network, which mediates cell shape, motility and proliferation and are key targets for cancer therapy. Changes in cytoskeletal organization correlate with proliferative capacity and invasiveness of cancer cells. These changes expectedly lead to altered…
-
Aggressiveness of cancer cells halted
Zebrafish-human communication shows that cancer cells lacking a signaling protein are less able to develop aggressive metastatic properties. This discovery has been made by molecular cell biologist Claudia Tulotta. PhD defence 14 June.
-
Exploring the mechanisms of metastatic onset for novel treatment strategies
This thesis represents a comprehensive investigation into the control of cancer stemness and metastatic initiation using a combination of advanced zebrafish xenograft models and in vitro assays.
-
Knowledge discovery from patient forums: gaining novel medical insights from patient experiences
Patients share valuable advice and experiences with their peers in online patient discussion groups.
-
Bob van de Water
Science
water_b@lacdr.leidenuniv.nl | +31 71 527 6223
-
networks controlled by Grainyhead like transcription factor in breast cancer subtypes
This project is funded by the Dutch Cancer Society. The project will be part of an ongoing research line aimed at identifying mechanisms of cancer therapy resistance and metastasis. In this project, it will be investigated how the Grainyhead family of transcription factors controls therapy response…
-
Development of a universal delivery system for tailor-made cancer vaccines
The potential of liposomal cancer vaccines
-
actomyosin contraction as a driving force of invasive lobular breast cancer
In this thesis, we used genetically engineered mouse models and a variety of cell-culture based assays to identify genes and pathways that are involved in the development and treatment of invasive lobular carcinoma (ILC).
-
Pedagogies of Prohibition: Time, Education, and the War on Drugs in Rio de Janeiro’s Zona Norte
Benjamin Fogarty-Valenzuela published the article 'Pedagogies of Prohibition: Time, Education, and the War on Drugs in Rio de Janeiro’s Zona Norte' in Cultural Anthropology 37. The article’s three sections focus on three forms of temporal control—busyness, punctuality, and rhythm—and each demonstrates…
-
PLGA-based particulate vaccine delivery systems for immunotherapy of cancer
Promotores: W. Jiskoot, F. Ossendorp
-
xenograft model: identification of novel mechanisms driving prostate cancer metastasis
Prostate cancer (PCa) is one of the most prevalent cancer in males.
-
Growth Fund invests many millions in faster and more sustainable (cancer) drug development
On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…
-
Fluorescence Polarization Activity-Based Protein Profiling on Retaining Glycosidases
Glycosidases are important enzymes in the turnover of polysaccharides and glycoconjugates, and are involved in a range of human pathologies including genetic disorders such as Gaucher and Pompe disease, but also in various cancers.
-
Fighting cancer with light (and a drug that self-assembles into nanoparticles)
Chemotherapy that does not harm the body, but effectively fights cancer cells: that is the goal of chemist Sylvestre Bonnet and his team. During his PhD research, chemist Xuequan Zhou brought that goal a little closer. He developed molecules that, upon injection in the bloodstream, self-assemble into…
-
Screening enormous databases to find a cure for cancer
Pharmaceutical research should make more use of data science, says Gerard van Westen, postdoctoral fellow at the Leiden Academic Centre for Drug Research (LACDR). ‘If we want to have better drugs, we should start with data.’
-
Pharmacometabolomics; prediction of system-wide multi-biomarker drug response
The lack of success of new CNS drugs in clinical development is in part due to the complexity of the CNS, unexpected side effects, difficulties for drugs to penetrate the brain, but also by the lack of biomarkers.
-
Pharmacogenomics in drug development: implementation and application of PKPD model based approaches
Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh
-
Light and nanoparticles against cancer
Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…
-
Video lecture: What is cancer?
Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.
-
Tracking genes to fight breast cancer
PhD student Esmee Koedoot studied the underlying processes responsible for metastases in a dangerous type of breast cancer. She hopes to find new possibilities to fight the disease. In December 2019 she obtained her doctorate cum laude.
-
mRNA and drug delivery with lipid-based nanoparticles
This thesis focuses on the application of lipid-based nanomedicine in drug delivery, including small molecular antitumor drugs and biomacromolecules including mRNA, and evaluates their biological performance.
-
Mario van der Stelt
Science
m.van.der.stelt@chem.leidenuniv.nl | +31 71 527 4768
-
Gerard van Westen
Science
gerard@lacdr.leidenuniv.nl | +31 71 527 3511
-
Madeline Kavanagh
Science
m.e.kavanagh@lic.leidenuniv.nl | +31 71 527 3527
-
24-hour rhythms in drug exposure and effect
Although rarely considered by the pharmaceutical industry or clinicians, 24-hour rhythms in physiology are a factor of potential influence on the pharmacokinetics and pharmacodynamics of drugs.
-
Spatial (3-D) CNS drug distribution in vivo
Another research line is the development of a spatial CNS drug distribution model, by ultimately including the 3-dimensional anatomical organization of the CNS.
-
Why don't drugs make it to the market?
How can we extend the drug residence time to combat diseases more effectively?
-
Drug discovery 3.0: more effective and humane
Discovering effective new drugs is a long, expensive and uncertain process. Laura Heitman wants to improve this by finding out more about how drugs bind to proteins that play a role in disease. She calls it ‘drug discovery 3.0’. Inaugural lecture on 9 December.